{"protocolSection": {"identificationModule": {"nctId": "NCT00123955", "orgStudyIdInfo": {"id": "AG0030"}, "secondaryIdInfos": [{"id": "R01AG018915", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01AG018915"}, {"id": "2R01AG018915-05", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/2R01AG018915-05"}], "organization": {"fullName": "Wake Forest University Health Sciences", "class": "OTHER"}, "briefTitle": "PIE II: Pharmacological Intervention in the Elderly II", "officialTitle": "Exercise Intolerance in Elderly Diastolic Heart Failure"}, "statusModule": {"statusVerifiedDate": "2019-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-04"}, "primaryCompletionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-07-22", "studyFirstSubmitQcDate": "2005-07-22", "studyFirstPostDateStruct": {"date": "2005-07-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-02-06", "resultsFirstSubmitQcDate": "2015-02-06", "resultsFirstPostDateStruct": {"date": "2015-02-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-02-12", "lastUpdatePostDateStruct": {"date": "2019-02-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Wake Forest University", "class": "OTHER"}, "collaborators": [{"name": "National Institute on Aging (NIA)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).", "detailedDescription": "Exercise intolerance due to HFPEF is a major cause of disability among older Americans. Several lines of evidence suggest that aldosterone antagonism may improve exercise tolerance in HFPEF. Therefore, the primary aim of this study is to test the hypothesis that spironolactone will improve exercise tolerance and quality of life in elderly patients with isolated HFPEF. A total of 72 participants aged 60 or older will be randomized to receive either spironolactone 25mg daily or a placebo."}, "conditionsModule": {"conditions": ["Diastolic Heart Failure", "Heart Failure, Congestive"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 80, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Spironolactone", "interventionNames": ["Drug: Spironolactone"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Spironolactone", "description": "25mg tablet daily for 9 months", "armGroupLabels": ["1"], "otherNames": ["Aldactone"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo tablet daily for 9 months", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Exercise Intolerance", "description": "Peak exercise VO2", "timeFrame": "Baseline, 4 and 9 months"}, {"measure": "Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire-total Score", "description": "The Minnesota Living with Heart Failure Questionnaire (MLHF) is a self-administered disease-specific questionnaire for patients with Heart Failure, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.\n\nScale of 0-105:The higher the score the worse the heart failure related Quality of Life.", "timeFrame": "Baseline, 4 and 9 months"}], "secondaryOutcomes": [{"measure": "Concentric Left Ventricular Remodeling", "description": "Left ventricle measurements by MRI:\n\nMass/end diastolic volume ratio: g/ml", "timeFrame": "Baseline, 9 month"}, {"measure": "Left Ventricular Diastolic Stiffness", "description": "Echocardiography Doppler measurement of left ventricular diastolic function:\n\nEarly mitral annulus velocity (lateral) (Ea; cm/s)", "timeFrame": "Baseline, 4 month and 9 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Ambulatory\n* Medically stable\n* Ages 60 or older\n* Diagnosis of diastolic heart failure\n\nExclusion Criteria:\n\n* Valvular heart disease\n* Significant change in cardiac medication within the past 4 weeks\n* Uncontrolled hypertension\n* Recent or debilitating stroke\n* Cancer or other noncardiovascular conditions with life expectancy less than 2 years\n* Anemia\n* Elevated serum potassium\n* Renal insufficiency\n* Psychiatric disease (uncontrolled major psychoses, depression, dementia, or personality disorder)\n* Allergy to spironolactone; currently taking spironolactone or any aldosterone antagonist\n* Plans to leave area within 1 year\n* Refuses informed consent\n* Failure to pass screening tests: pulmonary function, echocardiogram, or exercise\n* Contra-indications to magnetic resonance imaging \\[MRI\\] (indwelling metal-containing prosthesis; pacemaker or defibrillator; history of welding occupation; uncontrollable claustrophobia)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "60 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dalane W. Kitzman, MD", "affiliation": "Professor of Internal Medicine, Cardiology, Director of Echocardiography, Wake Forest University Health Sciences", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Wake Forest University Baptist Medical Center", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}]}, "referencesModule": {"references": [{"pmid": "12413374", "type": "BACKGROUND", "citation": "Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002 Nov 6;288(17):2144-50. doi: 10.1001/jama.288.17.2144."}, {"pmid": "2007704", "type": "BACKGROUND", "citation": "Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991 Apr;17(5):1065-72. doi: 10.1016/0735-1097(91)90832-t."}, {"pmid": "11179524", "type": "BACKGROUND", "citation": "Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M, Enright PL; Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001 Feb 15;87(4):413-9. doi: 10.1016/s0002-9149(00)01393-x."}, {"pmid": "11094035", "type": "BACKGROUND", "citation": "Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28;102(22):2700-6. doi: 10.1161/01.cir.102.22.2700. Erratum In: Circulation 2001 Jan 23;103(3):476."}, {"pmid": "10471456", "type": "BACKGROUND", "citation": "Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001."}, {"pmid": "11835920", "type": "BACKGROUND", "citation": "Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P, Caruso B, Zardini P. Relation of aldosterone \"escape\" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002 Feb 15;89(4):403-7. doi: 10.1016/s0002-9149(01)02261-5."}, {"pmid": "23150511", "type": "BACKGROUND", "citation": "Kitzman DW, Herrington DM, Brubaker PH, Moore JB, Eggebeen J, Haykowsky MJ. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension. 2013 Jan;61(1):112-9. doi: 10.1161/HYPERTENSIONAHA.111.00163. Epub 2012 Nov 12."}, {"pmid": "19379452", "type": "BACKGROUND", "citation": "Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail. 2009 Mar-Apr;15(2):68-74. doi: 10.1111/j.1751-7133.2009.00056.x."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months"}, {"id": "FG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "37"}, {"groupId": "FG001", "numSubjects": "34"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months"}, {"id": "BG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "80"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.0", "spread": "7.3"}, {"groupId": "BG001", "value": "71.7", "spread": "7.3"}, {"groupId": "BG002", "value": "70.8", "spread": "7.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "64"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Peak VO2 (ml/kg/min)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/kg/min", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.5", "spread": "2.9"}, {"groupId": "BG001", "value": "13.3", "spread": "2.9"}, {"groupId": "BG002", "value": "13.4", "spread": "2.9"}]}]}]}, {"title": "Workload (Watts)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Watts", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63", "spread": "26"}, {"groupId": "BG001", "value": "60", "spread": "26"}, {"groupId": "BG002", "value": "62", "spread": "26"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Exercise Intolerance", "description": "Peak exercise VO2", "populationDescription": "The outcome measure data uses data from all participants with 4 and/or 9 month follow-up. Thirty-seven participants randomized to spironolactone and 35 participants randomized to placebo completed 4 months of follow-up, and 37 participants randomized to spironolactone and 34 participants randomized to placebo completed 9 months of follow-up.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml/kg/min", "timeFrame": "Baseline, 4 and 9 months", "groups": [{"id": "OG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.5", "spread": "2.9"}, {"groupId": "OG001", "value": "13.3", "spread": "2.9"}]}]}, {"title": "4 months", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.6", "spread": "3.5"}, {"groupId": "OG001", "value": "13.5", "spread": "3.4"}]}]}, {"title": "9 months", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.8", "spread": "3.2"}, {"groupId": "OG001", "value": "13.9", "spread": "3.7"}]}]}]}, {"type": "PRIMARY", "title": "Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire-total Score", "description": "The Minnesota Living with Heart Failure Questionnaire (MLHF) is a self-administered disease-specific questionnaire for patients with Heart Failure, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.\n\nScale of 0-105:The higher the score the worse the heart failure related Quality of Life.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 4 and 9 months", "groups": [{"id": "OG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "32", "spread": "21"}, {"groupId": "OG001", "value": "28", "spread": "19"}]}]}, {"title": "4 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "29", "spread": "20"}, {"groupId": "OG001", "value": "29", "spread": "23"}]}]}, {"title": "Final- 9 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "29", "spread": "18"}, {"groupId": "OG001", "value": "25", "spread": "18"}]}]}]}, {"type": "SECONDARY", "title": "Concentric Left Ventricular Remodeling", "description": "Left ventricle measurements by MRI:\n\nMass/end diastolic volume ratio: g/ml", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/ml", "timeFrame": "Baseline, 9 month", "groups": [{"id": "OG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": ".4"}, {"groupId": "OG001", "value": "1.7", "spread": ".5"}]}]}, {"title": "9 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": ".4"}, {"groupId": "OG001", "value": "1.6", "spread": ".4"}]}]}]}, {"type": "SECONDARY", "title": "Left Ventricular Diastolic Stiffness", "description": "Echocardiography Doppler measurement of left ventricular diastolic function:\n\nEarly mitral annulus velocity (lateral) (Ea; cm/s)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm/s", "timeFrame": "Baseline, 4 month and 9 month", "groups": [{"id": "OG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "spread": "2.1"}, {"groupId": "OG001", "value": "6.8", "spread": "1.4"}]}]}, {"title": "4 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "spread": "2.1"}, {"groupId": "OG001", "value": "6.8", "spread": "1.4"}]}]}, {"title": "9 month", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.4", "spread": "2.2"}, {"groupId": "OG001", "value": "6.6", "spread": "1.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Spironolactone", "description": "Spironolactone\n\nSpironolactone: 25mg tablet daily for 9 months", "seriousNumAffected": 6, "seriousNumAtRisk": 42, "otherNumAffected": 0, "otherNumAtRisk": 42}, {"id": "EG001", "title": "Placebo", "description": "Placebo\n\nPlacebo: Placebo tablet daily for 9 months", "seriousNumAffected": 6, "seriousNumAtRisk": 38, "otherNumAffected": 0, "otherNumAtRisk": 38}], "seriousEvents": [{"term": "Hospitalization for chest pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Elective surgery", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}]}, {"term": "Hospitalization for shortness of breath", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 38}]}, {"term": "Hospitalization for syncope", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Hospitalization for hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Hospitalization for angioedema", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Death", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Motor vehicle accident", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Dalane Kitzman", "organization": "Wake Forest Baptist Health", "email": "dkitzman@wakehealth.edu", "phone": "336-716-3274"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Diastolic Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013148", "term": "Spironolactone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}], "browseLeaves": [{"id": "M15943", "name": "Spironolactone", "asFound": "Tape", "relevance": "HIGH"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}